Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
Chemomab (CMMB) Mid-Stage Study for NASH Meets Primary Goal
04:44pm, Wednesday, 04'th Jan 2023 Zacks Investment Research
Chemomab's (CMMB) phase II study evaluating CM-101 in NASH patients met its primary endpoint of safety and tolerability.
5 Most Expensive Health Care Stocks You Should Worry About
01:10pm, Tuesday, 03'rd Jan 2023 Benzinga
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
The RSI is a momentum indicator, which compares a stock's strength on days when
Why These 7 Healthcare Stocks Could Soar in 2023
07:22am, Monday, 02'nd Jan 2023
With the healthcare sector poised to grow significantly in the coming years, healthcare stocks to buy present a fantastic opportunity for investors. Healthcare is something that everyone will need at
5 Top Stocks for January
10:45am, Sunday, 01'st Jan 2023 The Motley Fool
Now is the time to begin crafting your watch list for 2023.
Madrigal Pharmaceuticals Setting The Standard
12:36pm, Monday, 26'th Dec 2022
Madrigal's lead drug candidate was already expected to be successful in its pivotal trial. FDA approval would then be earned by a positive on one of the trial's dual endpoints.
This Stock That Tripled in 2022 Could Rocket Even Higher in 2023
10:21am, Monday, 26'th Dec 2022 The Motley Fool
Potential suitors with heaps of cash to spend are lining up to get a closer look at this company's results.
This Stock That Tripled in 2022 Could Rocket Even Higher in 2023
05:21am, Monday, 26'th Dec 2022
Potential suitors with heaps of cash to spend are lining up to get a closer look at this company's results.
Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector
12:46pm, Friday, 23'rd Dec 2022 Benzinga
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies.
The RSI is a momentum indicator, which compares a stock's strength on days when p
Why Madrigal Pharmaceuticals Was a Top Stock This Week
12:03pm, Friday, 23'rd Dec 2022 The Motley Fool
Biotech bulls stampeded the company following its latest clinical update.
Madrigal Pharmaceuticals: Upcoming Windfall Profits
08:31am, Friday, 23'rd Dec 2022
Like an early Christmas/Hanukkah present, Madrigal shares rallied over 268% in one session due to the positive MAESTRO-NASH data. The shares continue to move in the ensuing day. Coupled with the stron
Why Madrigal Pharmaceuticals Was a Top Stock This Week
07:03am, Friday, 23'rd Dec 2022
Biotech bulls stampeded the company following its latest clinical update.
Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More
01:07pm, Thursday, 22'nd Dec 2022 Zacks Investment Research
Pipeline updates from Madrigal (MDGL) and Entrada (TRDA) are the key highlights from the biotech sector during the past week.
7 Drug Stocks That Will Soar in 2023
06:00am, Thursday, 22'nd Dec 2022
Choosing the best drug stocks to buy can be dicey because drug stocks have disadvantages and advantages. On the negative side, you often have to wait many years for promising drugs to prove themselves
Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program
09:15pm, Wednesday, 21'st Dec 2022 GlobeNewswire Inc.
CONSHOHOCKEN, Pa., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that it has raised $259 million in gross equity (or $255 million in net proceeds) f
Madrigal: Next Steps After 'Wow' Data In NASH
11:03am, Wednesday, 21'st Dec 2022
On Monday, Madrigal Pharmaceuticals announced a best-case dataset from its phase 3 trial in NASH. This opens up a Huge market for the company.
